Elizabeth M. Jaffee and Philip D. Greenberg opened AACR IO 2026 with a look at cancer vaccines and the...
Clinical trials were a major focus of the AACR Virtual Annual Meeting I, spanning nine plenary sessions over the two-day...
In the United States, nearly 24,000 people are estimated to receive a brain or nervous system cancer diagnosis in 2020....
Epithelial ovarian cancer is by far the most common ovarian cancer subtype, accounting for 90 percent of ovarian cancers. The...
“The field of cell therapy is one of the most exciting fields in translational medicine,” began Katayoun Rezvani, MD, PhD,...
Bladder cancer is a common malignancy originating in the bladder, a hollow organ located in the abdomen that stores urine. It is the sixth most prevalent cancer in the United...
Over the course of the two-day AACR Virtual Annual Meeting I, more than 61,000 people from 140 countries around the...
Over the past decade, immune checkpoint inhibitors have transformed cancer care for a variety of tumor types. This form of immunotherapy can lead to long-lasting...
At the time of this writing, more than 3.3 million individuals have been diagnosed with COVID-19, and more than 222,000 have died from the...
A short time after Mallika Lala, PhD, finished her presentation titled “Pembrolizumab 400 mg Q6W dosing: First clinical outcomes...
The excitement surrounding this week’s AACR Virtual Meeting I – which drew more than 61,000 people on the first day – can’t stop us from delivering the latest edition of Editors’...